

# OUR PRODUCTS



BIOACTIVE FRACTION PRODUCTS FROM DLBS

*dexa group*

# Dexa Medica Group Indonesia



# Dedication of a young Pharmacist



  
**ISTANA PRESIDEN REPUBLIK INDONESIA**  
**D J A K A R T A**

—  
**DIREKTUR KABINET PRESIDEN**

dengan ini mengundang Jang Mulia/Saudara beserta Njonja untuk menghadiri pelantikan lulusan Wadajib Militer Darurat (WAMILDA) angkatan Ke-I yang akan dilakukan oleh P. J. M. Presiden/Panglima Tertinggi bertempat di halaman Istana Merdeka pada hari Djum'at tanggal 29 Djanuari 1960 djam 09.00 pagi.

Djakarta, 25 Djanuari 1960.

1. Kendaraan masuk dari Djl. Segara.  
2. Pakalan lengkap.

*P.O. - B + Pita Djawa*





# dexa group



Non Oncology  
UK MHRA Certified  
Europe, ASEAN  
Market  
Indonesia (JKN,  
Private)



Oncology  
European Design  
Facility  
ASEAN Market  
Indonesia (JKN,  
Private)



Herbal  
Bio Active Fraction



Top 3 pharma company  
in Indonesia, Active in  
12 other countries.  
Active in JKN Market

*beta pharmacon*

Tablet & Liquid  
Indonesia GMP  
Indonesia JKN  
Market



Leader in  
BE-BA Lab,  
with ISO  
17025  
certificate



PT FERRON PAR PHARMACEUTICALS  
Innovation, Quality and Care

innovation, quality & care

# END TO END COMPETENCY



Dexa Development Center



Dexa Laboratory of Biomolecular Science



Manufacturing Site, Palembang



Manufacturing Site, Cikarang



Manufacturing Site, Karawang



Distribution Center, Cikarang



# Expertise for The Promotion of Health *dexa group*

**Indonesian  
Pharmaceutical  
company  
since 1969**  
with an integrated  
value chain activities



A big family of  
**>7000**  
members



**Top 3**  
pharmaceutical  
companies  
in Indonesia



Active in 3  
continents:  
**Asia, Africa,  
Europe**



**Partner  
of choice**

in various strategic  
alliance models with  
53 alliance partners

**+700**  
approved  
marketing  
authorization  
across the  
world

Manufacturing facilities inspected  
and approved by highest  
regulatory standards :  
**PIC/s authority, UK-MHRA,  
Australian TGA,  
Bavarian RP-Germany**



**Invested  
~5%**  
of sales revenue  
on R&D across  
formulations,  
analytical, biological  
research and clinical

**5** **state-of-the art  
manufacturing facilities**  
with modern machineries/  
instruments and increased  
capacity

**>600**  
R&D, clinical,  
medical and  
regulatory  
professionals  
working in Dexa  
Group



is a market leader  
in generic drugs in  
Indonesia

**Rhinos SR®**  
a sustain  
released  
product  
is a market  
leader in rhinitis  
allergic market  
in Indonesia.

Strong market  
penetration  
capability with  
distribution  
coverage of  
**19,000+**  
pharmacies &  
hospitals in  
Indonesia

**Bio-molecular  
Science  
Research Center**  
dedicated to enhance  
the life of human beings  
using sources of living  
organisms such as plants,  
animals, and microbes  
from Indonesia

**Biological  
products  
development  
with state  
of the art  
technologies**

**42  
patents &  
+1250  
trademarks**  
worldwide

**Metformin XR**  
a value added  
product, exported  
to UK in 2008,  
now covers  
25% market share  
in UK.



**+120**  
Strategically selected  
R&D pipeline of high  
value products.



We are making progress

# Our contribution

1

- **Generic Medicines**
  - Branded Generics
  - Non Branded Generics
  - Sustained-release
- **Life Saving Medicines**
- **Herbal Medicines**
  - Standardized Herbal
  - Phyto Pharmaca



2

- **Pharmaceutical Raw Materials**
  - Modern Herbal Extract
  - Lyophilized Bulk Sterile Omeprazole



3

- **Export of Finished Dosage Forms to ASEAN, Africa, UK**







# Dexa Development Center



- Importance of innovation to build our competitive advantages
- Product dossier that comply with the respected regulatory agency
  - First Generics
  - New Drug Delivery System



- Dexe Laboratories of Biomolecular Sciences started in 2005
- Committed only on Indonesian vast biodiversity
- Supported with pre-clinical and clinical trials
- The first Bioactive Fraction was launched in 2011: Inlacin and Disolf
- Several patents were granted in Indonesia and other countries

# DLBS Extraction Plant



- HE Minister of Health inaugurated the plant on 20 August 2013
- **CPBBAOB – IEBA** certified
- More than 20 bio active fractions are produced, regularly



# FERRON FACILITY

## EUROPEAN COMPLIANCE STANDARD

- 2017 Primaniyarta Award
- UK MHRA Compliance Facility
- Manufacture Tablet, Injectable and Active Pharmaceutical Ingredient
- Export Regularly to UK → Metformin Sustain Release Glucient SR
- 25% Market Share Metfromin Sustain Release in UK Market





# PT FONKO INTERNATIONAL PHARMACEUTICALS

A MEMBER OF DEXA GROUP



[www.fonko-pharma.com](http://www.fonko-pharma.com)

# FONKO BRIEF DESCRIPTION

**Manufacturing Facility Dedicated for Oncology/Cytotoxic Products :**  
Capability to handle products up to OEB 5

**Dosage Forms: Sterile Solution & Freeze Dried in Vial :**

- Aseptic Filling, under C-RABS
- Vial Range 5 ml to 50 ml
- Terminal Sterilization capability
- Integrated Freeze Dryer:
  - Water-based or tert-butanol based
  - Automatic loading system with row by row transfer system

**Annual Capacity: 4 Million Vials (1 million freeze dried)**

The biggest Oncology Manufacturer in Indonesia. Future extension space.



- ✓ Designed with EU, TGA and PIC/S GMP standard
- ✓ Conceptual Design by International GMP Consultants
- ✓ UpToDate quality system



## OUR STATE OF THE ART FACILITY



Compounding Isolator with negative pressure integrated with vessel



C-RABS with positive pressure to maintain product sterility



Sterility Test Isolator with validated decontamination cycle



Filling Machine with 100% check weighing system



Freeze Dryer with Automated Loading Unloading System

# PRODUCTS

<b>PRODUCTS</b>	<b>ACTIVE INGREDIENTS</b>
PACLITAXEL	Paclitaxel 30 mg (vial 5 ml) Paclitaxel 100 mg (vial 16.7 ml) Paclitaxel 300 mg (vial 50 ml)
GEMCITABINE	Gemcitabine 200 mg Gemcitabine 1000 mg
BORTEZOMIB	Bortezomib 3,5 mg
BENDAMUSTINE	Bendamustine HCl 25 mg Bendamustine HCl 100 mg
VINORELBINE	Vinorelbine tartrate 13.85 mg equivalent 10 mg (vial 1 ml)
ZOLEDRONIC ACID	Zoledronic acid monohydrate 4,264 mg equivalent 4 mg zoledronic acid (vial 5 ml)
CA.FOLINAT	Calcium Folate 10.8 mg/ml equivalent 10 mg/ml folic acid (vial 5 ml)
EPIRUBICINE	Epirubicin HCl 10 mg ( vial 5 ml) Epirubicin HCl 50 mg (vial 25 ml)
CARBOPLATIN	Carboplatin 150 mg (vial 15 ml) Carboplatin 450 mg (vial 45 ml)
DOCETAXEL	Docetaxel 20 mg (vial 1 ml) Docetaxel 80 mg (vial 4 ml)



# PRODUCTS (Under Development)

PRODUCTS	ACTIVE INGREDIENTS
CISPLATIN	Cisplatin 10 mg (vial 10 ml) Cisplatin 50 mg (vial 50 ml)
OXALIPLATIN	Oxaliplatin 50 mg (vial 10 ml) Oxaliplatin 100 mg (vial 20 ml)
PEMETREXED	Pemetrexed 100 mg Pemetrexed 500 mg
FLUOROURACIL	Fluorouracil 250 mg (5 ml) Fluorouracil 500 mg (10 ml)





# COLLABORATION OPPORTUNITIES

- **CMO Business**
- **Collaborative Network → Partner of Choice**
  - In-licensing of dossiers →  
for registration, re-licensing,  
tech- transfer, redevelopment
  - Co-development partner

Contact: [business@dexagroup.com](mailto:business@dexagroup.com)

Thank you very much

